Format

Send to

Choose Destination
Cancer Discov. 2019 Jun 4. doi: 10.1158/2159-8290.CD-NB2019-065. [Epub ahead of print]

Maintenance Olaparib New Standard in Pancreatic Cancer?

[No authors listed]

Abstract

In a phase III trial, olaparib maintenance therapy significantly extended progression-free survival and duration of response in patients with BRCA-mutated metastatic pancreatic cancer who responded to platinum-based chemotherapy, compared with a placebo. Based on the findings, which were presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, IL, maintenance olaparib is likely to become a new treatment option for these patients.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center